The SeroPrEP Study

Are you a provider for a patient on oral or injectable PrEP who has received a reactive or detectable result on an HIV test?

Your patient may be eligible for the SeroPrEP study. Click here to learn more.

Have you received a positive test for HIV, even though you take PrEP pills or injections?

We need your help. Please join the SeroPrEP study to help us understand more about how this happens and how it may impact HIV treatment outcomes. To learn more about the study or to enroll, click here

Pre-exposure Prophylaxis or PrEP is highly effective for the prevention of HIV. However, some cases of HIV infection have occurred despite PrEP use. The SeroPrEP study is being done to better understand why some people acquire HIV while taking oral PrEP or CAB LA, and how this may impact HIV treatment outcomes.

Participants in this study must meet the following criteria:

Age 18 years or above
One or more HIV tests suggesting that HIV-1 infection has occurred. Such tests may include RNA tests, antigen tests, or antibody tests.
Use or receipt of

Injection | Contraception Choices CAB-LA (Apretude) in the last 18 months

or

Unknown Oral PrEP (Descovy or Truvada) in the last 3 months

→If you have a patient who may be eligible for the SeroPrEP study, click here to more Information for Providers

→If you believe you may qualify to participate in this study, click here to learn more INFORMATION FOR PATIENTS

*SeroPrEP enrolls participants from all 50 U.S. states and Puerto Rico.